Cargando…

Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report

RATIONALE: The potential efficacy of apatinib in patients with advanced triple-negative breast cancer (TNBC) has been observed in a previous phase II clinical study. However, there is no study to evaluate its efficacy and safety in TNBC patients with brain metastasis (BM). Here we report one case th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Wang, Shan-Bing, Lei, Kai-Jian, Jiang, Mao-Qiong, Jia, Yu-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358397/
https://www.ncbi.nlm.nih.gov/pubmed/30681587
http://dx.doi.org/10.1097/MD.0000000000014182
_version_ 1783391996114632704
author Li, Ting
Wang, Shan-Bing
Lei, Kai-Jian
Jiang, Mao-Qiong
Jia, Yu-Ming
author_facet Li, Ting
Wang, Shan-Bing
Lei, Kai-Jian
Jiang, Mao-Qiong
Jia, Yu-Ming
author_sort Li, Ting
collection PubMed
description RATIONALE: The potential efficacy of apatinib in patients with advanced triple-negative breast cancer (TNBC) has been observed in a previous phase II clinical study. However, there is no study to evaluate its efficacy and safety in TNBC patients with brain metastasis (BM). Here we report one case that apatinib exhibited excellent antitumor effects in a breast cancer patient with brain metastasis, with no serious treatment-associated with adverse event. PATIENT CONCERNS: In this case report, one Chinese woman who was diagnosed with stage IV TNBC with multiple bone, lung, and brain metastases was unable to tolerate chemotherapy and refused whole-brain radiation therapy (WBRT) due to her poor physical condition. She had previously undergone radical mastectomy and intravenous chemotherapy. DIAGNOSES: Triple-negative breast cancer. INTERVENTIONS: The patient underwent left radical mastectomy with ipsilateral axillary lymph node dissection, and the following adjuvant chemotherapy, but developed multiple bone, lung, and brain metastases. Due to her poor physical condition, chemotherapy was not eligible for her. And she refused WBRT and chose to take low-dose apatinib (250 mg, oral, daily) monotherapy. OUTCOMES: After 2 months of treatment, the symptom of headache and vomiting relieved and all the brain metastases (BMs) lesions disappeared. LESSONS: Low-dose apatinib monotherapy may be an alternative treatment for patients with poor physical condition. Preclinical and clinical studies should be conducted to further evaluate the mechanism and efficacy of apatinib in the treatment of BM from TNBC, as well as to explore the optimal dose of the drug.
format Online
Article
Text
id pubmed-6358397
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63583972019-02-15 Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report Li, Ting Wang, Shan-Bing Lei, Kai-Jian Jiang, Mao-Qiong Jia, Yu-Ming Medicine (Baltimore) Research Article RATIONALE: The potential efficacy of apatinib in patients with advanced triple-negative breast cancer (TNBC) has been observed in a previous phase II clinical study. However, there is no study to evaluate its efficacy and safety in TNBC patients with brain metastasis (BM). Here we report one case that apatinib exhibited excellent antitumor effects in a breast cancer patient with brain metastasis, with no serious treatment-associated with adverse event. PATIENT CONCERNS: In this case report, one Chinese woman who was diagnosed with stage IV TNBC with multiple bone, lung, and brain metastases was unable to tolerate chemotherapy and refused whole-brain radiation therapy (WBRT) due to her poor physical condition. She had previously undergone radical mastectomy and intravenous chemotherapy. DIAGNOSES: Triple-negative breast cancer. INTERVENTIONS: The patient underwent left radical mastectomy with ipsilateral axillary lymph node dissection, and the following adjuvant chemotherapy, but developed multiple bone, lung, and brain metastases. Due to her poor physical condition, chemotherapy was not eligible for her. And she refused WBRT and chose to take low-dose apatinib (250 mg, oral, daily) monotherapy. OUTCOMES: After 2 months of treatment, the symptom of headache and vomiting relieved and all the brain metastases (BMs) lesions disappeared. LESSONS: Low-dose apatinib monotherapy may be an alternative treatment for patients with poor physical condition. Preclinical and clinical studies should be conducted to further evaluate the mechanism and efficacy of apatinib in the treatment of BM from TNBC, as well as to explore the optimal dose of the drug. Wolters Kluwer Health 2019-01-25 /pmc/articles/PMC6358397/ /pubmed/30681587 http://dx.doi.org/10.1097/MD.0000000000014182 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Li, Ting
Wang, Shan-Bing
Lei, Kai-Jian
Jiang, Mao-Qiong
Jia, Yu-Ming
Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title_full Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title_fullStr Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title_full_unstemmed Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title_short Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
title_sort significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358397/
https://www.ncbi.nlm.nih.gov/pubmed/30681587
http://dx.doi.org/10.1097/MD.0000000000014182
work_keys_str_mv AT liting significantresponseoflowdoseapatinibmonotherapyinbrainmetastasesoftriplenegativebreastcanceracasereport
AT wangshanbing significantresponseoflowdoseapatinibmonotherapyinbrainmetastasesoftriplenegativebreastcanceracasereport
AT leikaijian significantresponseoflowdoseapatinibmonotherapyinbrainmetastasesoftriplenegativebreastcanceracasereport
AT jiangmaoqiong significantresponseoflowdoseapatinibmonotherapyinbrainmetastasesoftriplenegativebreastcanceracasereport
AT jiayuming significantresponseoflowdoseapatinibmonotherapyinbrainmetastasesoftriplenegativebreastcanceracasereport